ABCL logo

ABCELLERA BIOLOGICS INC

ABCLNASDAQ
🏆 #1451 by market capEarnings Nov 4US Equity
$14.83▲ $0.96 (+6.50%)
After hours · at close
🔔
Track ABCL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.5%
7d▲ 17.2%
14d▲ 30.0%
30d▲ 30.7%
ytd▲ 334.8%
1y▲ 204.4%
🏦Market Cap
$4.53B
Small Cap
📈Revenue Growth (YoY)
+160.6%
High Growth
📊Gross Margin
75.0%
High
💵FCF Margin
-271.2%
Thin
⚖️P/S Ratio
64.2x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$14.70 – $15.10
52-Week Range
$2.75 – $14.23
Volume
$1.80B
Avg Volume
$1.97B
Shares Outstanding
305.4M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$75M
Last Q Revenue
$4M
P/E Ratio
-25.8
P/S Ratio
64.2x
EPS (TTM)
$-0.54
Dividend Yield
0.00%

Why Investors Own ABCL

  • ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 34% gross margin and 7% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABCL logo

ABCELLERA BIOLOGICS INC

ABCL
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$75M▲ +0.9% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
34.4%▲ +4.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$10M▲ +0.9% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5M▲ +0.9% YoY
StockOtter · stockotter.space

About ABCELLERA BIOLOGICS INC

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$16.47
▲ +11.1% Upside
High Target$20.01
Low Target$13.47
Based on 37 analysts

Latest News & Updates

🚀
Reuters·2h ago

ABCELLERA BIOLOGICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift ABCL price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ABCELLERA BIOLOGICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.